An observational, multicentre study of cabazitaxel in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel (CAPRISTANA)

• DOI: 10.1111/bju.14509
• Publication Date: 2018-08-11T07:28:08Z
• Authors: Joan Carles; Angelika Pichler; Hana Korunkova; Antoaneta Tomova; Marwan Ghosn; Fadi El Karak; Joseph Makdessi; Irina Koroleva; Gisoo Barnes; Denise Bury; Ayse Özatilgan; Simon Hitier; Jana Katolicka
• Keywords: Cabazitaxel

To obtain routine clinical practice data on cabazitaxel usage patterns for patients with metastatic castration-resistant prostate cancer (mCRPC) and to describe physician-assessed effectiveness, health-related quality of life (HRQoL) safety.CAPRISTANA was an international, observational cohort study examining use the treatment mCRPC. Effectiveness assessed by overall survival (OS), progression-free (PFS), time failure (TTF) disease control rate. HRQoL using Functional Assessment Cancer Therapy-Prostate questionnaire (FACT-P) three-level European Quality Life (EQ-5D-3L). Safety adverse event (AE) reporting.A total 189 were treated across 54 centres between April 2012 June 2016. At baseline, 58.7% had ≥1 comorbidity, 93.7% Eastern Cooperative Oncology Group performance status ≤1, 60.1% a Gleason score at diagnosis ≥8. Patients received median 6 cycles; 84.7% as second-line therapy. The OS, PFS TTF 13.2, 5.6 4.4 months, respectively. Cabazitaxel led in 52.9% patients. maintained (40.3%) or improved (32.2%) 72.5% based FACT-P scores. Interestingly, 53.6% reported pain improvement further 21.2% cancer-specific most common treatment-related grade ≥3 AEs neutropenia (7.9%) anaemia (2.1%).Patients CAPRISTANA similar outcomes safety profiles compared large phase III trials. Most scores; >70% control.